{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:35:52Z","timestamp":1767771352366,"version":"build-2065373602"},"reference-count":47,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Foundation for Science and Technology (FCT)","award":["UI\/BD\/152282\/2021","UIDB\/00215\/2020","UIDP\/00215\/2020","LA\/P\/0064\/2020"],"award-info":[{"award-number":["UI\/BD\/152282\/2021","UIDB\/00215\/2020","UIDP\/00215\/2020","LA\/P\/0064\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The association of well-differentiated gastro-entero-pancreatic neuroendocrine neoplasia (WD GEP-NEN) with metabolic syndrome (MetS), abdominal obesity, and fasting glucose abnormalities was recently described. However, whether obesity and metabolic syndrome risk factors are associated with GEP-NEN adverse outcomes and the poorer prognosis was unknown. The present study aimed to evaluate whether the presence of MetS or any of its individual components at WD GEP-NEN diagnosis influenced disease outcomes. A cohort of patients with non-localized WD GEP-NETs (n = 81), was classified according to the primary tumor site (gastrointestinal or pancreatic), pathological grading (G1 (Ki67 \u2264 2%) and G2 (3% \u2264 Ki67 \u2264 20%) (WHO 2010)), disease extension (loco-regional or metastatic disease), presence of hormonal secretion syndrome (functioning or non-functioning), and evaluated for the presence of MetS criteria at diagnosis. MetS was present in 48 (59.3%) patients. During a median follow-up of 95.0 months (16.8\u2013262.5), 18 patients died of the disease (10 with MetS vs. 8 without MetS). Overall survival (OS) at 5 years was 87.1% (95% CI: 73.6\u201394.0) for MetS and 90.9% (95% CI: 74.4\u201397.0) for non-Mets group, while OS at 10 years was 72.5% (95% CI: 55.3\u201384.0) for MetS, and 76.4% (95% CI: 53.6\u201389.0) for non-MetS group. Progression-Free Survival (PFS) at 5 years was 45.9% (95% CI: 30.8\u201359.8) for MetS and 40.0% (95% CI: 21.3\u201358.1) for non-MetS group, and PFS at 10 years was 18.1% (95% CI: 7.0\u201333.5) for MetS and 24.4% (95% CI: 9.0\u201343.7) for non-MetS group. Waist circumference (WC), a surrogate measure for visceral obesity, was associated with significantly shorter PFS (HR = 1.03; 95% CI: 1.01\u20131.06), although did not influence OS (HR = 1.01; 95% CI: 0.97\u20131.06). The findings of this study reinforce a potential link between visceral obesity and GEP-NEN and further suggest that obesity could influence disease prognosis.<\/jats:p>","DOI":"10.3390\/jcm11206026","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T20:53:29Z","timestamp":1665608009000},"page":"6026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Visceral Obesity Is Associated with Shorter Progression-Free Survival in Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Neoplasia"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-305X","authenticated-orcid":false,"given":"Ana P.","family":"Santos","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (P.CCC), 4200-072 Porto, Portugal"},{"name":"Precancerous Lesions and Early Cancer Management Group, Research Center of IPO Porto (CI-IPOP), RISE@CI-IPO (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (P.CCC), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-5151","authenticated-orcid":false,"given":"Jessica","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Group, Research Center of IPO Porto (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (P.CCC), 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3171-4666","authenticated-orcid":false,"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[{"name":"Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (P.CCC), 4200-072 Porto, Portugal"},{"name":"Cancer Biology and Epigenetics Group, Research Centre of IPO Porto (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre (P.CCC), 4200-072 Porto, Portugal"},{"name":"Department of Pathology and Molecular Immunology, ICBAS\u2014School of Medicine and Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal"}]},{"given":"M. Helena","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Centro Hospitalar Universit\u00e1rio do Porto (CHUPorto), 4099-001 Porto, Portugal"},{"name":"UMIB\u2014Unit for Multidisciplinary Research in Biomedicine, ICBAS\u2014School of Medicine and Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-1831","authenticated-orcid":false,"given":"Mariana P.","family":"Monteiro","sequence":"additional","affiliation":[{"name":"UMIB\u2014Unit for Multidisciplinary Research in Biomedicine, ICBAS\u2014School of Medicine and Biomedical Sciences, University of Porto, 4050-313 Porto, Portugal"},{"name":"ITR\u2014Laboratory for Integrative and Translational Research in Population Health, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"NCD Countdown Collaborators (2018). NCD Countdown 2030: Worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet, 392, 1072\u20131088.","DOI":"10.1016\/S0140-6736(18)31992-5"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.21440","article-title":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","volume":"68","author":"Islami","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wu, S., Zhu, W., Thompson, P., and Hannun, Y.A. (2018). Evaluating intrinsic and non-intrinsic cancer risk factors. Nat. Commun., 9.","DOI":"10.1038\/s41467-018-05467-z"},{"key":"ref_5","first-page":"663","article-title":"The role of healthy lifestyle in cancer incidence and temporal transitions to cardiometabolic disease","volume":"3","author":"Cao","year":"2021","journal-title":"Cardio Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1470-2045(14)71123-4","article-title":"Global burden of cancer attributable to high body-mass index in 2012: A population-based study","volume":"16","author":"Arnold","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: Emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(14)60892-8","article-title":"Body-mass index and risk of 22 specific cancers: A population-based cohort study of 5.24 million UK adults","volume":"384","author":"Bhaskaran","year":"2014","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/dom.12124","article-title":"Diabetes and cancer: Two diseases with obesity as a common risk factor","volume":"16","author":"Garg","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.2337\/dc12-0336","article-title":"Metabolic syndrome and risk of cancer: A systematic review and meta-analysis","volume":"35","author":"Esposito","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.22534","article-title":"Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men","volume":"109","author":"Gong","year":"2007","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fonc.2019.00281","article-title":"Prediction of Metabolic Syndrome for the Survival of Patients With Digestive Tract Cancer: A Meta-Analysis","volume":"9","author":"Hu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13098-018-0398-2","article-title":"Metabolic syndrome is a risk factor for cancer mortality in the general Japanese population: The Jichi Medical School Cohort Study","volume":"11","author":"Watanabe","year":"2019","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"19880","DOI":"10.18632\/oncotarget.4166","article-title":"Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer","volume":"6","author":"You","year":"2015","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/s11605-010-1297-5","article-title":"Intra-abdominal fat predicts survival in pancreatic cancer","volume":"14","author":"Balentine","year":"2010","journal-title":"J. Gastrointest. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Santos, A.P., Santos, A.C., Castro, C., Raposo, L., Pereira, S.S., Torres, I., Henrique, R., Cardoso, H., and Monteiro, M.P. (2018). Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 10.","DOI":"10.3390\/cancers10090293"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000443169","article-title":"ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update","volume":"103","author":"Kianmanesh","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000098011","article-title":"Rare functioning pancreatic endocrine tumors","volume":"84","author":"Salazar","year":"2006","journal-title":"Neuroendocrinology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2105\/AJPH.2013.301597","article-title":"Body mass index categories and mortality risk in US adults: The effect of overweight and obesity on advancing death","volume":"104","author":"Borrell","year":"2014","journal-title":"Am. J. Public Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/S2213-8587(18)30150-5","article-title":"Worldwide burden of cancer attributable to diabetes and high body-mass index: A comparative risk assessment","volume":"6","author":"Zhou","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000443743","article-title":"Association between Metabolic Syndrome and Cancer","volume":"68","author":"Uzunlulu","year":"2016","journal-title":"Ann. Nutr. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41467-018-08159-w","article-title":"Central body fatness is a stronger predictor of cancer risk than overall body size","volume":"10","author":"Barberio","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Santos, A.P., Castro, C., Antunes, L., Henrique, R., Cardoso, M.H., and Monteiro, M.P. (2019). Disseminated Well-Differentiated Gastro-Entero-Pancreatic Tumors Are Associated with Metabolic Syndrome. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091479"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/annonc\/mdv505","article-title":"Risk factors for neuroendocrine neoplasms: A systematic review and meta-analysis","volume":"27","author":"Leoncini","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12967-021-03010-1","article-title":"Chronotype: What role in the context of gastroenteropancreatic neuroendocrine tumors?","volume":"19","author":"Barrea","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1056\/NEJMoa0801891","article-title":"General and abdominal adiposity and risk of death in Europe","volume":"359","author":"Pischon","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","article-title":"Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours","volume":"15","author":"Pape","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1002\/cam4.1507","article-title":"Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: A population-based study","volume":"7","author":"Cai","year":"2018","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.kjms.2018.05.009","article-title":"Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms","volume":"34","author":"Huang","year":"2018","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fmed.2020.00385","article-title":"Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors","volume":"7","author":"Pulvirenti","year":"2020","journal-title":"Front. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2124750","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Pusceddu, S., Vernieri, C., Di Maio, M., Prinzi, N., Torchio, M., Corti, F., Coppa, J., Buzzoni, R., Di Bartolomeo, M., and Milione, M. (2022). Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. Cancers, 14.","DOI":"10.3390\/cancers14010069"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lei, Y., Yi, Y., Liu, Y., Liu, X., Keller, E.T., Qian, C.-N., Zhang, J., and Lu, Y. (2017). Metformin targets multiple signaling pathways in cancer. Chin. J. Cancer, 36.","DOI":"10.1186\/s40880-017-0184-9"},{"key":"ref_38","first-page":"498","article-title":"Anticancer effects of metformin on neuroendocrine tumor cells in vitro","volume":"13","author":"Vlotides","year":"2014","journal-title":"Hormones"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/fon-2015-0077","article-title":"Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes","volume":"12","author":"Pusceddu","year":"2016","journal-title":"Future Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1210\/jc.2018-01455","article-title":"Type 2 diabetes in neuroendocrine tumors: Are biguanides and statins part of the solution?","volume":"104","author":"Gahete","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3389\/fonc.2019.00902","article-title":"Impact of metformin on systemic metabolism and survival of patients with advanced pancreatic neuroendocrine tumors","volume":"9","author":"Vernieri","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.gastro.2018.04.010","article-title":"Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and\/or Somatostatin Analogues","volume":"155","author":"Pusceddu","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2012.42.1677","article-title":"Metformin: A diabetes drug for cancer, or a cancer drug for diabetics?","volume":"30","author":"Martin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1387","DOI":"10.1002\/cnr2.1387","article-title":"Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients","volume":"4","author":"Ni","year":"2021","journal-title":"Cancer Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/ijc.32042","article-title":"Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)","volume":"144","author":"Vernieri","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.pathol.2019.07.001","article-title":"Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression","volume":"51","author":"Pereira","year":"2019","journal-title":"Pathology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"N\u00f6lting, S., Maurer, J., Sp\u00f6ttl, G., Aristizabal Prada, E.T., Reuther, C., Young, K., Korbonits, M., G\u00f6ke, B., Grossman, A., and Auernhammer, C.J. (2015). Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143830"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/6026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:52:59Z","timestamp":1760143979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/20\/6026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":47,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11206026"],"URL":"https:\/\/doi.org\/10.3390\/jcm11206026","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}